Insider · CIK 0001873879
Margaret M FitzPatrick
Files at VTGN (Vistagen Therapeutics, Inc.), ANTX (AN2 Therapeutics, Inc.). First filing May 29, 2025, latest Sep 2, 2026.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ANTX: AN2 Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | ANTXbuy AN2 Therapeutics, Inc. | $12k 2,098 shares | +24% | +432% from low-13% from high | |
| 39Weak | AN2 Therapeutics, Inc. | $10k 8,610 shares | - | +15% from low-31% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | ANTX AN2 Therapeutics, Inc. | POpen-market purchase Common Stock | +2,098 | $5.53 | $12k | 10,708 | 40 d ago |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +11,463 | - | - | 11,463 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -11,463 | - | - | 0 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +10,362 | - | - | 10,362 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -10,362 | - | - | 0 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +23,742 | - | - | 23,742 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -23,742 | - | - | 0 | Mar 23, 2026 |
| Feb 20, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +20,400 | $0.00 | $0 | 20,400 | Feb 23, 2026 |
| Sep 9, 2025 | VTGN Vistagen Therapeutics, Inc. | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +17,600 | $0.00 | $0 | 17,600 | Sep 11, 2025 |
| May 28, 2025 | ANTX AN2 Therapeutics, Inc. | POpen-market purchase Common Stock | +8,610 | $1.18 | $10k | 8,610 | May 29, 2025 |
| May 22, 2025 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +19,111 | $0.00 | $0 | 19,111 | May 23, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.